Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection

References

• TilghmanSLNierth-SimpsonENWallaceREnvironmental hormones: Multiple pathways for response may lead to multiple disease outcomesSteroids20107552052320466011
   PubMed Web of Science ®Google Scholar
• NicholsonRIMcClellandRARobertsonJFInvolvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancerEndocr Relat Cancer1999637338710516852
   PubMed Web of Science ®Google Scholar
• PedramARazandiMLevinERNature of functional estrogen receptors at the plasma membraneMol Endocrinol2006201996200916645038
   PubMed Web of Science ®Google Scholar
• HammesSRLevinERExtranuclear steroid receptors: Nature and actionsEndocr Rev20072872674117916740
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative GroupEffects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trialsLancet20053651687171715894097
   PubMed Web of Science ®Google Scholar
• OsborneCKElledgeRMFuquaSAWEstrogen receptors in breast cancer therapySci Med199633241
   Google Scholar
• ArteagaCLOsborneCKGrowth factors as mediators of estrogen/antiestrogen action in human breast cancer cellsLippmanMEDicksonRBRegulatory mechanisms in breast cancer: Advances in cellular and molecular biology of breast cancerBoston, MAKluwer Academic1991
   Google Scholar
• EllisPASaccani-JottiGClarkeRInduction of apoptosis by tamoxifen and ICI 182780 in primary breast cancerInt J Cancer1997726086139259399
   PubMed Web of Science ®Google Scholar
• WiebeVJOsborneCKFuquaSAWTamoxifen resistance in breast cancerCrit Rev Oncol Hematol1993141731888397846
   PubMed Web of Science ®Google Scholar
• HorwitzKBJacksonTABainDLNuclear receptor coactivators and corepressorsMol Endocrinol199610116711779121485
   PubMed Web of Science ®Google Scholar
• EncarnacionCACioccaDRMcGuireWLMeasurement of steroid hormone receptors in breast cancer patients on tamoxifenBreast Cancer Res Treat1993262372468251648
   PubMed Web of Science ®Google Scholar
• HullDFIIIClarkGMOsborneCKMultiple estrogen receptor assays in human breast cancerCancer Res1983434134166847780
   PubMed Web of Science ®Google Scholar
• BoeddinghausIMDowsettMComparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitorsJ Steroid Biochem Mol Biol200179859111850211
   PubMed Web of Science ®Google Scholar
• BuzdarAHowellAAdvances in aromatase inhibition: Clinical efficacy and tolerability in the treatment of breast cancerClin Cancer Res200172620263511555572
   PubMed Web of Science ®Google Scholar
• KaoYCCamLLLaughtonCABinding characteristics of seven inhibitors of human aromatase: A site-directed mutagenesis studyCancer Res199656345134608758911
   PubMed Web of Science ®Google Scholar
• JohnstonSRDowsettMAromatase inhibitors for breast cancer: Lessons from the laboratoryNat Rev Cancer2003382183114668813
   PubMed Web of Science ®Google Scholar
• JengMHShupnikMABenderTPEstrogen receptor expression and function in long-term estrogen-deprived human breast cancer cellsEndocrinology1998139416441749751496
   PubMed Web of Science ®Google Scholar
• SantenRJSongRXZhangZAdaptive hypersensitivity to estrogen: Mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatmentJ Steroid Biochem Mol Biol20059515516516024245
   PubMed Web of Science ®Google Scholar
• MouridsenHGiobbie-HurderAGoldhirschALetrozole therapy alone or in sequence with tamoxifen in women with breast cancerN Engl J Med200936176677619692688
   PubMed Web of Science ®Google Scholar
• HowellARobertsonJFQuaresmaAJFulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatmentJ Clin Oncol2002203396340312177099
   PubMed Web of Science ®Google Scholar
• OsborneCKPippenJJonesSEDouble-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trialJ Clin Oncol2002203386339512177098
   PubMed Web of Science ®Google Scholar
• HowellAOsborneCKMorrisCICI 182,780 (Faslodex): Development of a novel, “pure” antiestrogenCancer20008981782510951345
   PubMed Web of Science ®Google Scholar
• RobertsonJFNicholsonRIBundredNJComparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentyl sulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancerCancer Res2001616739674611559545
   PubMed Web of Science ®Google Scholar
• WakelingAEDukesMBowlerJA potent specific pure antiestrogen with clinical potentialCancer Res199151386738731855205
   PubMed Web of Science ®Google Scholar
• BorrasMLaiosIel KhissiinAEstrogenic and antiestrogenic regulation of the half-life of covalently labeled estrogen receptor in MCF-7 breast cancer cellsJ Steroid Biochem Mol Biol1996572032138645630
   PubMed Web of Science ®Google Scholar
• DauvoisSWhiteRParkerMGThe antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttlingJ Cell Sci1993106137713888126115
   PubMed Web of Science ®Google Scholar
• HowellABerghJInsights into the place of fulvestrant for the treatment of advanced endocrine responsive breast cancerJ Clin Oncol2010284548455020855842
   PubMed Web of Science ®Google Scholar
• CoombesRCHallEGibsonLJA randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancerN Engl J Med20043501081109215014181
   PubMed Web of Science ®Google Scholar
• HowellACuzickJBaumMResults of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancerLancet2005365606215639680
   PubMed Web of Science ®Google Scholar
• BaumMBudzarAUCuzickJAnastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trialLancet20023592131213912090977
   PubMed Web of Science ®Google Scholar
• ThurlimannBKeshaviahACoatesASA comparison of letrozole and tamoxifen in postmenopausal women with early breast cancerN Engl J Med20053532747275716382061
   PubMed Web of Science ®Google Scholar
• JonesSESeynaeveCHasenburgAResults of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancerAbstr 15. 31st Annual San Antonio Breast Cancer Symposium2008 Dec 10–14San Antonio, TX
   Google Scholar
• ReaDHasenburgASeynaeveCFive years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: The TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone-sensitive early breast cancerAbstr 11. 32nd Annual San Antonio Breast Cancer Symposium2009 Dec 9–13San Antonio, TX
   Google Scholar
• BlissJMKilburnLSColemanREDisease related outcome with long term follow-up: An updated analysis of the Intergroup Exemestane Study (IES)Abstract 12. 32nd Annual San Antonio Breast Cancer Symposium2009 Dec 9–13San Antonio, TX
   Google Scholar
• JonatWGnantMBoccardoFEffectiveness of switching from adjuvant tamoxifen to anastrozole in post-menopausal women with hormone-sensitive early-stage breast cancer: A meta-analysisLancet Oncol2006799199617138220
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNMartinoSRandomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17J Natl Cancer Inst2005971262127116145047
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNMartinoSA randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancerN Engl J Med20033491793180214551341
   PubMed Web of Science ®Google Scholar
• GoldhirschAIngleJNGelberRDThresholds for therapies: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009Ann Oncol2009201319132919535820
   PubMed Web of Science ®Google Scholar
• PerouCMSorlieTEisenMBMolecular portraits of human breast tumoursNature200040674775210963602
   PubMed Web of Science ®Google Scholar
• SorlieTPerouCMTibshiraniRGene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProc Natl Acad Sci200198108691087411553815
   PubMed Web of Science ®Google Scholar
• SorlieTTibshiraniRParkerJRepeated observation of breast tumor subtypes in independent gene expression data setsProc Natl Acad Sci20031008418842312829800
   PubMed Web of Science ®Google Scholar
• SotiriouCNeoSYMcShaneLMBreast cancer classification and prognosis based on gene expression profiles from a population-based studyProc Natl Acad Sci20031000103931039812917485
   PubMed Web of Science ®Google Scholar
• PaikSShakSTangGA multigene assay to predict recurrence of tamoxifen treated node-negative breast cancerN Engl J Med20043512817282615591335
   PubMed Web of Science ®Google Scholar
• MaXJWangZRyanPDA two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifenCancer Cell2004560761615193263
   PubMed Web of Science ®Google Scholar
• JansenMPFoekensJAvan StaverenILMolecular classification of tamoxifen resistant breast carcinomas by gene expression profilingJ Clin Oncol20052373274015681518
   PubMed Web of Science ®Google Scholar
• OhDSTroesterMAUsaryJEstrogen-regulated genes predict survival in hormone receptor-positive breast cancersJ Clin Oncol2006241656166416505416
   PubMed Web of Science ®Google Scholar
• LoiSHaibe-KainsBDesmedtCDefinition of clinically distinct molecular subtypes in estrogen receptor positive breast carcinomas through genomic gradeJ Clin Oncol2007251239124617401012
   PubMed Web of Science ®Google Scholar
• PaikSShakSTangCExpression of the 21 genes in the recurrence score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancerJ Clin Oncol20052316S51015659496
   PubMed Web of Science ®Google Scholar
• SotiriouCWirapatiPLoiSGene expression profiling in breast cancer: Understanding the molecular basis of intermediate histologic grade to improve prognosisJ Natl Cancer Inst200698112
   Google Scholar
• PaikSTangGShakSGene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancerJ Clin Oncol2006243726373416720680
   PubMed Web of Science ®Google Scholar
• AlbainKSBarlowWEShakSPrognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trialLancet Oncol201011556520005174
   PubMed Web of Science ®Google Scholar
• SymmansWFHatzisCSotiriouCGenomic index of sensitivity to endocrine therapy for breast cancerJ Clin Oncol2010284111411920697068
   PubMed Web of Science ®Google Scholar
• ChanrionMNegreVFontaineHA gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancerClin Cancer Res2008141744175218347175
   PubMed Web of Science ®Google Scholar
• MillerWRLarionovARenshawLGene expression profiles differentiating between breast cancer clinically responsive or resistant to letrozoleJ Clin Oncol2009271382138719224856
   PubMed Web of Science ®Google Scholar
• Mello-GrandMSinghVGhimentiCGene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically respectable breast cancerBreast Cancer Res Treat201012139941120428938
   PubMed Web of Science ®Google Scholar
• KokMLinnSLaarRComparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifenBreast Cancer Res Treat200911327528318311582
   PubMed Web of Science ®Google Scholar
• ShouJMassarwehSOsborneCKMechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancerJ Natl Cancer Inst20049692693515199112
   PubMed Web of Science ®Google Scholar
• OsborneCKBardouVHoppTARole of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancerJ Natl Cancer Inst20039535336112618500
   PubMed Web of Science ®Google Scholar
• EllisMJTaoYYoungOEstrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozoleJ Clin Oncol2006243019302516754938
   PubMed Web of Science ®Google Scholar
• Stemke-HaleKGonzalez-AnguloAMLluchAAn integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancerCancer Res2008686084609118676830
   PubMed Web of Science ®Google Scholar
• LoiSHaibe-KainsBMajjajSPIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancerProc Natl Acad Sci U S A2010107102081021320479250
   PubMed Web of Science ®Google Scholar
• di CosimoSBaselgaJPhosphoinositide 3-kinase mutations in breast cancer: A “good” activating mutation?Clin Cancer Res2009155017501919671849
   PubMed Web of Science ®Google Scholar
• KalinskyKJacksLMHeguyAPIK3CA mutation associates with improved outcome in breast cancerClin Cancer Res2009155049505919671852
   PubMed Web of Science ®Google Scholar
• EllisMJLinLCrowderRPhosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancerBreast Cancer Res Treat201011937939019844788
   PubMed Web of Science ®Google Scholar
• SalvesenHBCarterSLMannelqvistMIntegrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activationProc Natl Acad Sci U S A20091064834483919261849
   PubMed Web of Science ®Google Scholar
• CarptenJDFaberALHornCA transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature200744843944417611497
   PubMed Web of Science ®Google Scholar
• CourjalFCunyMSimony-LafontaineJMapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: Definition of phenotypic groupsCancer Res199757436043679331099
   PubMed Web of Science ®Google Scholar
• TheilletCAdelaideJLouasonGFGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancersGenes Chromosomes Cancer199372192267692948
   PubMed Web of Science ®Google Scholar
• Elbauomy ElsheikhSGreenARLambrosMBFGFR1 amplification in breast carcinomas: A chromogenic in situ hybridisation analysisBreast Cancer Res20079R2317397528
   PubMed Web of Science ®Google Scholar
• TurnerNPearsonASharpeRFGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancerCancer Res2010702085209420179196
   PubMed Web of Science ®Google Scholar
• MusgroveEASergioCMLoiSIdentification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancerPloS One20083e298718714337
   PubMed Web of Science ®Google Scholar
• ButtAJMcNeilCMMusgroveEADownstream targets of growth factor and oestrogen signalling and endocrine resistance: The potential roles of c-Myc, cyclin D1 and cyclin EEndocr Relat Cancer200512Suppl 1S47S5916113099
   PubMed Web of Science ®Google Scholar
• CheangMChiaSKVoducDKi67 index, HER2 status, and prognosis of patients with luminal B breast cancerJ Natl Cancer Inst200910173675019436038
   PubMed Web of Science ®Google Scholar
• BursteinHJPrestrudAASeidenfeldJAmerican Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancerJ Clin Oncol2010283784379620625130
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkClinical practice guidelines in oncology: Breast cancer Available at: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed 2010 May 25.
   Google Scholar
• VialeGReganMMDell’OrtoPCentral review of ER, PgR and HER2 in BIG 1-98 evaluating letrozole vs letrozole followed by tamoxifen vs tamoxifen followed by letrozole as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancerAbstract 76. 32nd Annual San Antonio Breast Cancer Symposium2009 Dec 9–13San Antonio, TX
   Google Scholar